ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its fourth quarter and full year 2024 financial results announcement for February 28, 2025, before market open. The company will host a conference call at 8:00 a.m. ET to discuss the results.
Key executives participating in the call include President and CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call toll-free at 800-579-2543 using Conference ID 4860276. A webcast will be available on the company's website under the Investors section, with a replay accessible for two weeks after the call.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 28 febbraio 2025, prima dell'apertura del mercato. L'azienda ospiterà una conferenza telefonica alle 8:00 a.m. ET per discutere i risultati.
I principali dirigenti che parteciperanno alla chiamata includono il Presidente e CEO Nikhil Lalwani, il CFO Stephen P. Carey e il Responsabile delle Malattie Rare Chris Mutz. Gli investitori possono accedere alla chiamata senza costi al numero 800-579-2543 utilizzando il Codice Conferenza 4860276. Sarà disponibile un webcast sul sito web dell'azienda nella sezione Investitori, con una registrazione accessibile per due settimane dopo la chiamata.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 28 de febrero de 2025, antes de la apertura del mercado. La compañía realizará una conferencia telefónica a las 8:00 a.m. ET para discutir los resultados.
Los principales ejecutivos que participarán en la llamada incluyen al Presidente y CEO Nikhil Lalwani, al CFO Stephen P. Carey y al Jefe de Enfermedades Raras Chris Mutz. Los inversores pueden acceder a la llamada de forma gratuita al 800-579-2543 utilizando el ID de Conferencia 4860276. Habrá un webcast disponible en el sitio web de la compañía en la sección de Inversores, con una repetición accesible durante dos semanas después de la llamada.
ANI Pharmaceuticals (NASDAQ: ANIP)는 2025년 2월 28일에 2024년 4분기 및 연간 재무 결과 발표를 시장 개장 전에 예정하고 있습니다. 회사는 오전 8시 ET에 결과를 논의하기 위한 전화 회의를 개최합니다.
전화 회의에 참여하는 주요 경영진으로는 사장 겸 CEO Nikhil Lalwani, CFO Stephen P. Carey, 희귀 질환 책임자 Chris Mutz가 있습니다. 투자자들은 800-579-2543로 무료로 전화를 걸어 회의 ID 4860276을 사용하여 회의에 참여할 수 있습니다. 회사 웹사이트의 투자자 섹션에서 웹캐스트를 이용할 수 있으며, 회의 후 2주간 재생할 수 있습니다.
ANI Pharmaceuticals (NASDAQ: ANIP) a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour le 28 février 2025, avant l'ouverture du marché. La société organisera une conférence téléphonique à 8h00 ET pour discuter des résultats.
Les principaux dirigeants participant à l'appel incluent le Président et CEO Nikhil Lalwani, le CFO Stephen P. Carey, et le Responsable des Maladies Rares Chris Mutz. Les investisseurs peuvent accéder à l'appel gratuitement au 800-579-2543 en utilisant l'ID de conférence 4860276. Un webinaire sera disponible sur le site de l'entreprise dans la section Investisseurs, avec une rediffusion accessible pendant deux semaines après l'appel.
ANI Pharmaceuticals (NASDAQ: ANIP) hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 28. Februar 2025 vor Markteröffnung geplant. Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Zu den Hauptverantwortlichen, die an dem Anruf teilnehmen, gehören Präsident und CEO Nikhil Lalwani, CFO Stephen P. Carey und Leiter der Seltenen Krankheiten Chris Mutz. Investoren können den Anruf gebührenfrei unter 800-579-2543 mit der Konferenz-ID 4860276 erreichen. Ein Webcast wird auf der Unternehmenswebsite im Bereich Investoren verfügbar sein, mit einer Wiederholung, die zwei Wochen nach dem Anruf zugänglich ist.
- None.
- None.
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows:
| Date | Friday, February 28, 2025 |
| Time | 8:00 a.m. ET |
| Toll free (U.S.) | 800-579-2543 |
| Conference ID | 4860276 |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-756-0554 and entering access code 4860276.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
When will ANI Pharmaceuticals (ANIP) release Q4 and full-year 2024 earnings?
How can investors access ANIP's Q4 2024 earnings call?
What time is ANI Pharmaceuticals' Q4 2024 earnings call?
How long will ANIP's Q4 2024 earnings call replay be available?
